1339 related articles for article (PubMed ID: 23601249)
1. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Bruix J; Raoul JL; Sherman M; Mazzaferro V; Bolondi L; Craxi A; Galle PR; Santoro A; Beaugrand M; Sangiovanni A; Porta C; Gerken G; Marrero JA; Nadel A; Shan M; Moscovici M; Voliotis D; Llovet JM
J Hepatol; 2012 Oct; 57(4):821-9. PubMed ID: 22727733
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Chen L; Su H; Shao H; Xu K; Liang S; Liu J
Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
Estfan B; Byrne M; Kim R
Am J Clin Oncol; 2013 Aug; 36(4):319-24. PubMed ID: 22547010
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY
BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors.
Li J; Wang L; Cong N; Shi C; Bu W; Song J; Chen H
Hepatogastroenterology; 2014 Jun; 61(132):954-7. PubMed ID: 26158148
[TBL] [Abstract][Full Text] [Related]
7. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Yada M; Masumoto A; Motomura K; Tajiri H; Morita Y; Suzuki H; Senju T; Koyanagi T
World J Gastroenterol; 2014 Sep; 20(35):12581-7. PubMed ID: 25253961
[TBL] [Abstract][Full Text] [Related]
8. Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
Yoon EL; Yeon JE; Lee HJ; Suh SJ; Lee SJ; Kang SH; Kang K; Yoo YJ; Kim JH; Yim HJ; Byun KS
J Clin Gastroenterol; 2014 Mar; 48(3):e22-9. PubMed ID: 24045282
[TBL] [Abstract][Full Text] [Related]
9. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
Bruix J; Tak WY; Gasbarrini A; Santoro A; Colombo M; Lim HY; Mazzaferro V; Wiest R; Reig M; Wagner A; Bolondi L
Eur J Cancer; 2013 Nov; 49(16):3412-9. PubMed ID: 23809766
[TBL] [Abstract][Full Text] [Related]
10. The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
Wörns MA; Koch S; Niederle IM; Marquardt JU; Nguyen-Tat M; Gamstätter T; Schuchmann M; Schulze-Bergkamen H; Galle PR; Weinmann A
Dig Liver Dis; 2013 May; 45(5):408-13. PubMed ID: 23182599
[TBL] [Abstract][Full Text] [Related]
11. Factors contributing to the overall survival in patients with hepatocellular carcinoma treated by sorafenib.
Tsukui Y; Mochizuki H; Hoshino Y; Kawakami S; Kuno T; Fukasawa Y; Iwamoto F; Hirose S; Yoshida T; Hosoda K; Suzuki Y; Hosoda K; Kojima Y; Hirose Y; Shindou K; Matsuda M; Yagawa S; Tawara A; Kobayashi M; Konishi T; Yamazaki T; Takahashi S; Fuji H; Enomoto N; Omata M
Hepatogastroenterology; 2012; 59(120):2536-9. PubMed ID: 22497953
[TBL] [Abstract][Full Text] [Related]
12. Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
Inghilesi AL; Gallori D; Antonuzzo L; Forte P; Tomcikova D; Arena U; Colagrande S; Pradella S; Fani B; Gianni E; Boni L; Laffi G; Di Costanzo F; Marra F
World J Gastroenterol; 2014 Jan; 20(3):786-94. PubMed ID: 24574751
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem.
Ziogas DC; Papadatos-Pastos D; Thillai K; Korantzis I; Chowdhury R; Suddle A; O'Grady J; Al-Khadimi G; Allen N; Heaton N; Ross PJ; Sarker D
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):48-55. PubMed ID: 27623000
[TBL] [Abstract][Full Text] [Related]
14. [Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
Turnes J; Díaz R; Hernandez-Guerra M; Gómez M; Castells L; Bustamante J; Espinosa MD; Fernández-Castroagudín J; Serrano T; Rendón P; Andrade R; Salgado M; Arenas J; Vergara M; Sala M; Polo BA; Granizo IM; Gonzálvez ML; Viudez A
Gastroenterol Hepatol; 2015 Apr; 38(4):263-73. PubMed ID: 25583146
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study.
Nada Y; Rashad N; Eissa M; Ghonaim A; Farag K; Saadawi I; Sheha A; El Gewaity M; Abdel-Rahman O
Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):99-107. PubMed ID: 29124987
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
[TBL] [Abstract][Full Text] [Related]
17. Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis.
Jeong SW; Jang JY; Shim KY; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Kim KH; Kim JH
Gut Liver; 2013 Nov; 7(6):696-703. PubMed ID: 24312711
[TBL] [Abstract][Full Text] [Related]
18. Clinical course of sorafenib treatment in patients with hepatocellular carcinoma.
Woo HY; Heo J; Yoon KT; Kim GH; Kang DH; Song GA; Cho M
Scand J Gastroenterol; 2012 Jul; 47(7):809-19. PubMed ID: 22563643
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Tajiri N; Satani M; Niizeki T; Aino H; Okamura S; Iwamoto H; Shimose S; Shirono T; Koga H; Torimura T;
Cancer Med; 2015 Dec; 4(12):1836-43. PubMed ID: 26471348
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]